Category Archives: OGN
Organon & Co (OGN) 25Q1 Update
Organon (OGN) reported 25Q1 GAAP diluted EPS of $0.33, down from $0.78 a year ago. Non-GAAP EPS was $1.02, down from $1.22. I had anticipated GAAP EPS of $0.61 and non-GAAP EPS of $0.92. Revenues of $1.51 billion declined 6.7% … Continue reading
Organon (OGN) 24Q4 Update
24Q4 revenues were $1.59 billion, up 3% at constant currency but down 0.4% YOY and 2.8% below my estimate. GAAP diluted EPS was $0.42, compared with 23Q4’s $2.13 and my estimate of $0.60. Non-GAAP EPS of $0.90 was above last … Continue reading
Organon & Co (OGN) 24Q3 Update
24Q3 revenues were $1.58 billion, up 4.1% year-over-year and up 5% at constant currency. GAAP diluted EPS was $1.38, compared with 23Q3’s $0.23, but above my estimate of $0.63. Non-GAAP EPS of $0.87 was even with last year, but below … Continue reading
Organon (OGN) 24Q2 Update
24Q2 revenues were $1.607 billion, down 0.1% year-over-year, but up 2% at constant currency. GAAP diluted EPS was $0.76, below 23Q2’s $0.95, but above my estimate of $0.67. Non-GAAP EPS of $1.12 was behind last year’s $1.31, but a penny … Continue reading
Organon (OGN) 24Q1 Update
24Q1 revenues were $1.622 billion, up 5.5% year-over-year, but up 7% at constant currency. GAAP diluted EPS was $0.78, above 23Q1’s $0.69 and my estimate of $0.77. Non-GAAP EPS of $1.22 was above last year’s $1.08 and also above my … Continue reading
Organon (OGN) 23Q3 Update
23Q3 revenues were $1.52 billion, down 1.2% YOY and also down 1% at constant currency. GAAP diluted EPS was $0.23, compared with 22Q3’s $0.90 and my estimate of $0.74. Non-GAAP EPS of $0.87 was below last year’s $1.32 and my … Continue reading
Organon & Co. (OGN) 23Q2 Update
23Q2 revenues were $1.61 billion, up 1.5% YOY and up 4% at constant currency. GAAP diluted EPS was $0.95, better than 22Q2’s $0.92 and above my estimate of $0.87. Non-GAAP EPS of $1.31 was higher than last year’s $1.25 and … Continue reading
Organon & Co. 23Q1 Update
23Q1 revenues were $1.538 billion, down 1.9% year-over-year, but up 3% at constant currency. GAAP diluted EPS was $0.69, below 22Q1’s $1.36 and below my estimate of $0.88. Non-GAAP EPS of $1.08 was below last year’s $1.65 and also below … Continue reading
Organon & Co (OGN) 22Q4 Update
22Q4 revenues were $1.485 billion, down 7.4% year-over-year, but up 1% at constant currency. GAAP diluted EPS was $0.43, below 21Q4’s $0.80 and below my estimate of $0.54. Non-GAAP EPS of $0.82 was below last year’s $1.18 and a penny … Continue reading
Organon & Co. (OGN) 22Q3 Update
22Q3 revenues were $1.537 billion, down 3.9% year-over-year, but up 3% at constant currency. GAAP diluted EPS was $0.92, below 21Q3’s $1.27, but above my estimate of $0.82. Non-GAAP EPS of $1.36 was below last year’s $1.61, but also above … Continue reading
Organon & Co (OGN) 22Q2 Update
22Q2 revenues of $1.585 billion were flat year-over-year, but up 5% at constant currency. GAAP EPS of $0.92, was below 21Q2’s $1.68 and also below my $1.11 estimate. Non-GAAP EPS of $1.25 was below last year’s $1.72 and also below … Continue reading
Organon 21Q3 Update
Organon reported 21Q3 GAAP EPS of $1.38 which exceeded my estimate of $1.31. Revenues were in line with my estimates and operating costs were lower, except for a $25 million increase associated with the acquisition of in-process research & development.
Organon (OGN) 21Q2 Update
21Q2 Performance in Line with Expectations; Raising Performance Rating and Lowering Price Target 21Q2 GAAP EPS of $1.68 was lower than 20Q2’s $2.14. Although sales increased 4.5% to $1.6 billion, costs were higher as a result of new tolling arrangements … Continue reading
Assessing the Impact of the Organon Spin-Off on Merck
Merck is progressing toward the spin-off of its subsidiary, Organon & Co., which is expected to be completed by the end of the June. Organon will include Merck’s women’s health products, biosimilars and certain established brands, most of which have … Continue reading
Merck Spin-Off of Organon Targeted for 21Q2
In recent weeks, Merck has been following through on its plan to spin-off its subsidiary, Organon & Co., to shareholders. On March 17, it filed its Form 10 registration statement related to the transaction. On March 24, it posted on … Continue reading